Format

Send to

Choose Destination
Eur Rev Med Pharmacol Sci. 2015;19(9):1583-8.

Efficacy of low-dose rituximab in combination with recombinant human thrombopoietin in treating ITP.

Author information

1
Department of Hematology, Qing-dao Central Hospital, Qing-dao, China. lyyycn@yeah.net.

Abstract

OBJECTIVE:

This work aims to observe the efficacy and safety of low-dose rituximab in combination with recombinant human thrombopoietin in treating immune thrombocytopenia (ITP).

PATIENTS AND METHODS:

Fourteen ITP patients were treated four times with 100 mg qw of rituximab in combination with 300 µg/kg/d ih recombinant human thrombopoietin (rhTPO) for 14 d. Platelet count in peripheral blood, serum immunoglobulin, and lymphocyte subgroups by flow cytometry were detected regularly both pre- and post-treatment.

RESULTS:

Among the 14 patients, seven complete responses, six responses, and one no response were obtained, with an overall response of 93%.

CONCLUSIONS:

Low-dose rituximab in combination with rhTPO is effective in treating ITP.

PMID:
26004596
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for European Review for Medical and Pharmacological Sciences
Loading ...
Support Center